Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 3/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.46 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.46 |
| ▸ | ADAMTS4 | O75173 | 4/20 | 0.45 |
| ▸ | MMP13 | P45452 | 3/20 | 0.45 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | IDH2 | P48735 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18152209 | 0.93 | KDM4E (0.44) | ACLYMCL1BCL2L1ADAMTS4MMP13 | |
| SCHEMBL18151924 | 0.92 | ADAMTS4 (0.49) | ACLYMCL1BCL2L1ADAMTS4MMP13 | |
| SCHEMBL18152274 | 0.89 | ADAMTS4 (0.47) | ACLYMCL1BCL2L1ADAMTS4MMP13 | |
| SCHEMBL18152036 | 0.87 | ADAMTS4 (0.48) | ACLYMCL1BCL2L1ADAMTS4MMP13 | |
| SCHEMBL18152267 | 0.86 | ACLY (0.55) | ACLYMCL1BCL2L1ADAMTS4MMP13 | |
| SCHEMBL23097485 | 0.84 | MCL1 (0.42) | MCL1BCL2L1ADAMTS4MMP13ADAMTS5 | |
| SCHEMBL18164602 | 0.82 | PLAU (0.42) | BCL2L1ADAMTS4MMP13MEN1GAA | |
| SCHEMBL18151710 | 0.82 | ADAMTS4 (0.45) | MCL1BCL2L1ADAMTS4MMP13ADAMTS5 | |
| SCHEMBL18174091 | 0.81 | CTSV (0.48) | MCL1ADAMTS4MMP13ADAMTS5 | |
| SCHEMBL18151707 | 0.80 | MCL1 (0.64) | ACLYMCL1BCL2L1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3285583-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3285583-B1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | UNIV MICHIGAN REGENTS (US) | 2021-03-17 | — | — | EP | disclosed |
| EP-3285583-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | The Regents of The University of Michigan (US) | 2018-02-28 | — | — | EP | disclosed |
| US-9884841-B2 | Small molecule inhibitors of Mcl-1 and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-02-06 | — | — | US | disclosed |
| US-9884841-B2 | Small molecule inhibitors of Mcl-1 and uses thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-02-06 | — | — | US | disclosed |
| WO-2016172218-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-10-27 | — | — | WO | disclosed |
| WO-2016172218-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2016-10-27 | — | — | WO | disclosed |
| US-20160304485-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
| US-20160304485-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304485-A1 | SMALL MOLECULE INHIBITORS OF MCL-1 AND USES THEREOF | MCL1, BCL2L1, BCL2L11 | ACLY 1272/4885MCL1 1/4885BCL2L1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.